1099 related articles for article (PubMed ID: 32380908)
1. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19.
Sengupta V; Sengupta S; Lazo A; Woods P; Nolan A; Bremer N
Stem Cells Dev; 2020 Jun; 29(12):747-754. PubMed ID: 32380908
[TBL] [Abstract][Full Text] [Related]
2. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
[TBL] [Abstract][Full Text] [Related]
3. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
[TBL] [Abstract][Full Text] [Related]
4. Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia.
Akbari A; Rezaie J
Stem Cell Res Ther; 2020 Aug; 11(1):356. PubMed ID: 32795359
[TBL] [Abstract][Full Text] [Related]
5. Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients.
Al-Khawaga S; Abdelalim EM
Stem Cell Res Ther; 2020 Oct; 11(1):437. PubMed ID: 33059757
[TBL] [Abstract][Full Text] [Related]
6. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells.
Shu L; Niu C; Li R; Huang T; Wang Y; Huang M; Ji N; Zheng Y; Chen X; Shi L; Wu M; Deng K; Wei J; Wang X; Cao Y; Yan J; Feng G
Stem Cell Res Ther; 2020 Aug; 11(1):361. PubMed ID: 32811531
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series.
Singh S; Chakravarty T; Chen P; Akhmerov A; Falk J; Friedman O; Zaman T; Ebinger JE; Gheorghiu M; Marbán L; Marbán E; Makkar RR
Basic Res Cardiol; 2020 May; 115(4):36. PubMed ID: 32399655
[TBL] [Abstract][Full Text] [Related]
8. Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia.
Zhang Y; Ding J; Ren S; Wang W; Yang Y; Li S; Meng M; Wu T; Liu D; Tian S; Tian H; Chen S; Zhou C
Stem Cell Res Ther; 2020 May; 11(1):207. PubMed ID: 32460839
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
10. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial.
Meng F; Xu R; Wang S; Xu Z; Zhang C; Li Y; Yang T; Shi L; Fu J; Jiang T; Huang L; Zhao P; Yuan X; Fan X; Zhang JY; Song J; Zhang D; Jiao Y; Liu L; Zhou C; Maeurer M; Zumla A; Shi M; Wang FS
Signal Transduct Target Ther; 2020 Aug; 5(1):172. PubMed ID: 32855385
[TBL] [Abstract][Full Text] [Related]
11. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.
Rogers CJ; Harman RJ; Bunnell BA; Schreiber MA; Xiang C; Wang FS; Santidrian AF; Minev BR
J Transl Med; 2020 May; 18(1):203. PubMed ID: 32423449
[TBL] [Abstract][Full Text] [Related]
12. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
13. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19.
Tang L; Jiang Y; Zhu M; Chen L; Zhou X; Zhou C; Ye P; Chen X; Wang B; Xu Z; Zhang Q; Xu X; Gao H; Wu X; Li D; Jiang W; Qu J; Xiang C; Li L
Front Med; 2020 Oct; 14(5):664-673. PubMed ID: 32761491
[TBL] [Abstract][Full Text] [Related]
14. Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicle Infusion for the Treatment of Respiratory Failure From COVID-19: A Randomized, Placebo-Controlled Dosing Clinical Trial.
Lightner AL; Sengupta V; Qian S; Ransom JT; Suzuki S; Park DJ; Melson TI; Williams BP; Walsh JJ; Awili M
Chest; 2023 Dec; 164(6):1444-1453. PubMed ID: 37356708
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19-Induced ARDS Patients: A Case Report.
Kim K; Bae KS; Kim HS; Lee WY
Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556900
[No Abstract] [Full Text] [Related]
16. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
17. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome.
Qu W; Wang Z; Hare JM; Bu G; Mallea JM; Pascual JM; Caplan AI; Kurtzberg J; Zubair AC; Kubrova E; Engelberg-Cook E; Nayfeh T; Shah VP; Hill JC; Wolf ME; Prokop LJ; Murad MH; Sanfilippo FP
Stem Cells Transl Med; 2020 Sep; 9(9):1007-1022. PubMed ID: 32472653
[TBL] [Abstract][Full Text] [Related]
18. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Atluri S; Manchikanti L; Hirsch JA
Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286
[TBL] [Abstract][Full Text] [Related]
19. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment.
Jayaramayya K; Mahalaxmi I; Subramaniam MD; Raj N; Dayem AA; Lim KM; Kim SJ; An JY; Lee Y; Choi Y; Raj A; Cho SG; Vellingiri B
BMB Rep; 2020 Aug; 53(8):400-412. PubMed ID: 32731913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
